Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers

Abstract

Spanish

French

Background:

Ginkgo biloba is one of the most popular herbal supplements in the world. The supplement has been shown to induce the enzymatic activity of CYP2C19, the main cytochrome P450 isozyme involved in voriconazole metabolism. Because this enzyme exhibits genetic polymorphism, the inductive effect was expected to be modulated by the CYP2C19 metabolizer status.

Objective:

To examine the possible effects of Ginkgo biloba as an inducer of CYP2C19 on single-dose pharmacokinetics of voriconazole in Chinese volunteers genotyped as either CVP2C19 extensive or poor metabolizers.

Methods:

Fourteen healthy, nonsmoking volunteers–7 CYP2C19 extensive metabolizers (2C19*1/2C19*1) and 7 poor metabolizers (2C19*2/2C19*2)–were selected to participate in this study. Pharmacokinetics of oral voriconazole 200 mg after administration of Ginkgo biloba 120 mg twice daily for 12 days were determined for up to 24 hours by liquid chromatography–electrospray tandem mass spectrometry in a 2-phase randomized crossover study with 4-week washout between phases.

Results:

For extensive metabolizers, the median value for voriconazole area under the plasma concentration–time curve from zero to infinity (AUC_0-00) was 5.17 μg•h/mL after administration of voriconazole alone and 4.28 μg•/mL after voriconazole with Ginkgo biloba (p > 0.05). The other pharmacokinetic parameters of voriconazole such as AUC_0-24, time to reach maximum concentration, half-life, and apparent clearance also did not change significantly for extensive metabolizers in the presence of Ginkgo biloba. Pharmacokinetic parameters followed a similar pattern for poor metabolizers.

Conclusions:

The results suggest that 12 days of treatment with Ginkgo biloba did not significantly alter the single-dose pharmacokinetics of voriconazole in either CYP2C19 extensive or poor metabolizers. Therefore, the pharmacokinetic interactions between voriconazole and Ginkgo biloba may have limited clinical significance.

Keywords

CYP2C19 genetic polymorphism Ginkgo biloba voriconazole

Get full access to this article

View all access options for this article.

References

Cuenca-Estrella

Rodríguez-Tudela

Mellado

Martínez-Suárez

Monzón

. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531–3.

Espinel-Ingroff

. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198–202.

Theuretzbacher

Ihle

Derendorf

. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649–63.

Herbrecht

Denning

Patterson

. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–15.

Hyland

Jones

Smith

. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540–7.

CYP2C19 information, www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=124020 (accessed 2008 Oct 16).

Human Cytochrome P450 Allele Nomenclature Committee. CYP2C19 allele nomenclature. www.cypalleles.ki.se/cyp2C19.htm (accessed 2008 Oct 16).

Gardiner

Begg

. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521–90.

Kurzawski

Gawrońska-Szklarz

Wrzeániewska

Siuda

Starzyńska

Droździk

. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006;62:877–80.

10.

Goldstein

Ishizaki

Chiba

. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59–64.

11.

De Morais

Wilkinson

Blaisdell

Meyer

Nakamura

Goldstein

. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594–8.

12.

Goldstein

Faletto

Romkes-Sparks

. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994;33:1743–52.

13.

Ferguson

de Morais

Benhamou

. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356–61.

14.

Sim

Risinger

Dahl

M-L

. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103–13.

15.

Rudberg

Mohebi

Hermann

Refsum

Molden

. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008;83:322–7.

16.

Rengelshausen

Banfield

Riedel

K-D

. Opposite effects of short-term and long-term St. John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78:25–33.

17.

Ikeda

Umemura

Kondo

Sekiguchi

Miyoshi

Nakashima

. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587–8.

18.

Diamond

Shiflett

Feiwel

. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000;81:668–78.

19.

Joshi

Kaul

. Alternative medicine: herbal drugs and their critical appraisal, I. Progress Drug Res 2001;56:1–76.

20.

Yin

Tomlinson

Waye

Chow

. Pharmacogenetics and herb–drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004;14:841–50.

21.

Hägg

Spigset

Dahlqvist

. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001;51:169–73.

22.

de Morais

. Wilkinson GR. Blaisdell J, Nakamura K, Meyer UA. Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419–22.

23.

de Morais

Goldstein

Xie

. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404–11.

24.

Garey

Peloquin

Godo

Nafziger

Amsden

. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Anti-microb Agents Chemother 1999;43:1152–5.

25.

Mikus

Schöwel

Drzewinska

. Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126–35.

26.

Uchida

Yamada

. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46:1290–8.

27.

Smith

Lin

Zheng

. An open trial of nifedipine–herb interactions with St. John's wort, ginseng, and Ginkgo biloba (abstract). Clin Pharmacol Ther 2001;69: P86.

28.

Kressman

Muller

Blume

. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002;54:661–9.

29.

Jiang

Williams

Liauw

. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425–32.

30.

Jacobs

Browner

. Ginkgo biloba: a living fossil. Am J Med 2000;108:341–2.

31.

Christen

Maixent

. What is Ginkgo biloba extract EGb 761? An overview—from molecular biology to clinical medicine. Cell Mol Biol (Noisy-le-grand) 2002;48:601–11.